References
- Francesc C, Sander HW, Fernández S. Intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravis. Expert Opin Pharmacother. 2023;24. just-accepted. DOI:10.1080/14656566.2023.2192867
- Vanoli F, Mantegazza R. What are the pharmacotherapeutic con- siderations for the treatment of myasthenia gravis? Expert Opin Pharmacother. 2022;23:1471–1474.
- Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68:837–841.
- Karelis G, Balasa R, De Bleecker JL, et al. A Phase 3 multicenter, prospective, open-label efficacy and safety study of immune glo- bulin (Human) 10% caprylate/chromatography purified in patients with myasthenia gravis exacerbations. Eur Neurol. 2019;81:223–230.
- Barth D, Nabavi Nouri M, Ng E, et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76:2017–2023.
- Murai H. J apanese clinical guidelines for myasthenia gravis: putting into practice. Clin Exp Immunol. 2015;6(1):21–31.